Category Venues

Amid Proposals, Ambassadors Fail To Unlock WIPO Talks On TK, GRs

The World Intellectual Property Organization committee working on ways to protect genetic resources and traditional knowledge opened a weeklong meeting yesterday by gathering country ambassadors to try to inject momentum into discussions. But after the session, it appeared that many delegations had restated known positions. Everybody seemed to agree on broad goals, but not on the way to reach them.

WIPO Director General Election: How It Works

On 6 March, the United Nations World Intellectual Property Organization will hold its once-every-six-year election for a director general, a prized post in the multilateral system. Tomorrow (4 February), the candidates will face member states and take questions. Intellectual Property Watch explains the process.

WIPO Issues Tribute To Pete Seeger

The World Intellectual Property Organization has posted a tribute to legendary American folk singer, songwriter and activist Pete Seeger, who died on 27 January at the age of 94.

Move On Data Protection Or Fail On TTIP, EU Parliament Chair Says

At the Munich Security Conference a year ago, there was a considerable first push for the Transatlantic Trade and Investment Partnership (TTIP). Eight months after the start of official TTIP negotiations and with the Snowden revelations in between, the tone at the 50th edition of the high-level foreign policy event in Munich is somewhat changed.

MSF: AstraZeneca Pullout Of Neglected Disease R&D Proof System Broken

Following news reports that pharmaceutical producer AstraZeneca will end its spending on early stage research and development for tuberculosis, malaria and neglected tropical diseases, Médecins Sans Frontières issued a statement saying the move is further proof that substantive change to the global pharmaceutical R&D system is needed.

New Study Makes Case for Innovative Medicines

A new pharmaceutical industry-backed study draws attention to the value of innovative medicines in reducing healthcare costs and to the wider society that goes beyond clinical and personal values. However, in middle income countries, national prioritisation and improvements in healthcare infrastructure are needed to maximise the value of medicinal innovation, the study found.